A Previously Unrecognized Protein-Protein Interaction between TWEAK and CD163: Potential Biological Implications
T he TNF and TNFR superfamilies play important roles in the development and regulation of the immune system and are implicated in diverse physiologic processes such as apoptosis, cell proliferation, and bone remodeling (1) (2) (3) . TWEAK (TNFS12) is a "TNF-like weak inducer" of apoptosis (hence its name) through a non-death domain-dependent mechanism (Refs. 2 and 4; see also HBNC Gene Family Nomenclature; http://www.gene.ucl.ac.uk/nomenclature/genefamily/tnftop.html). It also mediates angiogenesis (5, 6) and inflammation (7, 8) . In particular, interactions between TWEAK and monocytes have been reported (9, 10) .
However, despite this relatively extensive literature, the complete biological effects of TWEAK remain largely unknown because cells lacking the corresponding receptor (11) (12) (13) have also been shown to be TWEAK sensitive. Death receptor 3 (DR3; TNFRS12), a member of the TNFR family containing an intracellular death domain, was initially suggested as a TWEAK-binding molecule (14, 15) , but subsequent studies opposed these results (12) . More recently, fibroblast growth factor inducible 14 (Fn14)/ TweakR has been reported to control TWEAK-associated proliferation of endothelial cells and angiogenesis (16) . Supporting these findings, Nakayama et al. have shown that Fn14/TweakR mediates TWEAK-induced programmed cell death (17) . However, because Fn14/TweakR lacks the cytoplasmic death domain, the ligand-receptor structural basis is still unclear. Finally, Polek et al. (18) have demonstrated that TWEAK mediates signal transduction and linear differentiation of monocyte/macrophage cells lacking Fn14/ TweakR, suggesting that such cells contain an alternative TWEAK receptor, TweakR2. Interestingly, TweakR2 and Fn14/TweakR induce a differential activation of signaling pathways (18) . Nevertheless, the identification of such a putative receptor remains elusive.
In this study, we report the screening of a random combinatorial peptide library (19 -23) on TWEAK to identify new TWEAK-binding proteins. We show that TWEAK binds specifically to several consensus peptide motifs that are homologous to the scavenger receptor cysteine-rich (SRCR) 5 CD163 protein (also called M130 and RM3/1; Refs. 24 -28) . Consistently, TWEAK binding to purified CD163 was dose dependent and blocked by either the peptide motif mimicking CD163 or by an anti-CD163 mAb. Interestingly, in competition assays TWEAK binding to Fn14/TweakR is competed out by preincubation with soluble CD163 and vice versa. Next, we used cells sensitive to TWEAK but Fn14/TweakR deficient (CD14-positive human monocytes) to demonstrate that TWEAK interacts with CD163 expressed on the cell surface. This association can partially inhibit the activation of monocytes by an anti-CD163 Ab. Then, we show that TWEAK-mediated apoptosis in IFN-␥-treated HT29 cells (12) can be prevented when TWEAK is preincubated with monocytes but not when an anti-CD163 mAb or the peptide that mimics CD163 is added to the culture medium. Finally, we demonstrate that CD163-transfected Chinese hamster ovary (CHO) cells bind 125 I-labeled recombinant human TWEAK ( 125 I-rHuTWEAK), but other SRCR members (CD5 and CD6) do not. This process is reverted in a dose-dependent manner by the addition of unlabeled TWEAK; haptoglobin (Hp) and hemoglobin (Hb) complex (Hp-Hb); peptide mimicking CD163 and anti-CD163 Ab. Together, these findings indicate a possible functional link between TWEAK and CD163.
Materials and Methods
Reagents rHuTWEAK and the goat polyclonal anti-human TWEAK Ab were purchased from Peprotech. CD163 was purified from solubilized human spleen membranes as described (29) . Anti-CD163 Abs were obtained as follows: clone GHI/61 from BD Biosciences, clone Ki-M8 from BMA Biomedicals, clone10D6 from Vector Laboratories, and clone AM-3K as described (30) . Secondary Abs used were HRP-conjugated anti-goat IgG from Sigma-Aldrich and HRP-conjugated anti-mouse IgG from Bio-Rad. FITC-conjugated anti-human CD14 was purchased from Miltenyi Biotec, purified and PE-conjugated anti-Fn14/TweakR (PE-ITEM-4) and antihuman CD5 (clone UCHT2) Abs were purchased from eBiosciences, and Cyanine 3 (Cy3)-conjugated AffiniPure F(abЈ) 2 donkey anti-goat IgG (HϩL) was purchased from Jackson ImmunoResearch Laboratories. Isotype controls (PE-mIgG1/k, PE-mIgG2b/k, and FITC-mIgG2a) and the antihuman CD6 Ab (clone M-T605) were purchased from BD Pharmingen. CWDDGWSFC (CD163-like peptide) and CRKFRDEATC (used as a control peptide) were purchased from Genemed Synthesis. Human epidermal growth factor (EGF), human IL-2, and human IL-11 and their correspondent Abs (goat anti-human) were from R&D Systems. Human Hb and Hp phenotype 2-2 were from Sigma-Aldrich. FuGENE (Roche) was used for transfection procedures. Na 125 I (3.7 GBq/ml) was purchased from GE Healthcare Bioscience. Human CD163 (transcript variant 1)-pCMV6-XL4, Fn14-pCMV6-XL5, and human CD5 full-length cDNA clones were purchased from OriGene Technologies, and human CD6 was from Invitrogen Life Technologies.
Phage display screening and phage binding assays
A phage display random peptide library based on the vector fUSE5 displaying the insert CX 7 C (where C is cysteine and X is any residue) (23) was used in the screening (31, 32) ; phage input was 2.5 ϫ 10 9 transforming units (TU). The TWEAK-GST recombinant fusion protein (18) was coated on microtiter wells (Linbro; ICN Pharmaceuticals) as described (21) at 4.5 g per 50 l of PBS. The original cyclic phage peptide inserts of seven amino acid residues were analyzed by multiple sequence alignment by using the Clustal W software (European Molecular Biology Laboratory; 32, 33). The selected motifs were then searched against protein databases (National Center for Biotechnology Information (NCBI); www.ncbi. nlm.nih.gov/BLAST/) to search for similarity to known human proteins. Phage binding assays on rHuTWEAK, TWEAK-GST, GST, and BSA (Fraction V, Sigma-Aldrich) were conducted as described (21) . Briefly, proteins were immobilized on microtiter wells overnight at 4°C at decreasing concentrations (from 5.0 to 0.5 g/well). Wells were washed twice with PBS, blocked with PBS plus 3% BSA for 2 h at room temperature, and incubated with 10 9 TU of CWDDGWSFC, CLWTDDGYC, CYWG-DDGFC, CWWFDDGYC, and CRWADDGFC phage clones or insertless fd-tet phage in 50 l PBS containing 2% BSA. After 1 h at room temperature, the wells were washed 10 times with PBS and bound phage was recovered by bacterial infection. Goat polyclonal anti-human TWEAK Ab (Peprotech) at 2 g/ml was used to evaluate the inhibition of phage binding for 90 min at room temperature. In an alternative experimental design, either CWDDGWSFC phage or fd-tet was coincubated with mouse antihuman CD163 mAb (clone GHI/61; 10 g/ml) or a mouse IgG1 control isotype and then added to rHuTWEAK or BSA-coated wells.
Protein-protein interaction assays
CD163 or Fn14/TweakR was coated onto a 96-well plate at 2 g/ml and rHuTWEAK was added at 2 g/ml. VEGF and BSA were used as coating negative controls. After 2 h, the binding of TWEAK to CD163 or Fn14/ TweakR was detected by ELISA with an anti-TWEAK Ab (diluted at 1/1,000). Parallel ELISAs were performed by using a 1/150 dilution of an anti-CD163 Ab followed by an HRP-conjugated anti-mouse IgG to confirm CD163 coating or by adding EGF, IL-2 or IL-11 as alternate ligands for CD163 and recognizing the cytokines with the corresponding Abs. Bound proteins were analyzed by ELISA on an automated reader at 450 nm (Bio-Tek Instruments). For experiments showing dose-dependent TWEAK binding to CD163 or Fn14/TweakR, increasing concentrations of rHu TWEAK were added to the wells (3, 10, 30, 100, 300 and 1,000 ng/ml). In competition experiments, soluble CD163 or soluble Fn14/TweakR (at a range from 0.05 M to 15 M) was preincubated with rHuTWEAK for 30 min and then added to the coated Fn14/TweakR or CD163, respectively. To test inhibition of TWEAK binding to CD163 by anti-CD163 Abs, CD163 protein was coated, blocked with PBS containing 2% BSA, and incubated with anti-CD163 Abs (clones Ki-M8, GHI/61, and 10D6) at 200 ng/ml for 30 min at room temperature. Control IgGs were used at same conditions. Then, rHuTWEAK was added onto the wells for 2 h and developed with anti-TWEAK (1/1,000 dilution). TWEAK binding to CD163 was evaluated by preincubation of rHuTWEAK with CWWDGWSFC or control peptides added at 0, 3, 6, 10, 30, 60, 100, and 300 M).
PBMCs and monocyte purification
Fresh human PBMCs were isolated from 50 -60 ml of buffy coat from normal volunteer blood donors (Gulf Coast Blood Bank, Houston, TX) by using Ficoll-Paque (Pharmacia Biotech) density gradients. Monocytes were isolated from the PBMC population by positive selection using a CD14-positive magnetic bead separation system (Miltenyi Biotec). Cells were used immediately for flow cytometry or cultured in AIM-V medium (Invitrogen Life Technologies) for other assays.
Flow cytometric analysis for CD163 expression and other SRCR expression
CD14-positive monocytes were incubated on ice for 1 h with PE-labeled mouse anti-human-CD163 (clone GHI/61), FITC-conjugated anti-human 5 Abbreviations used in this paper: SRCR, scavenger receptor cystein rich; CHO, Chinese hamster ovary; Cy3, cyanine 3; EGF, epidermal growth factor; Fn14, fibroblast growth factor inducible 14; Hb, hemoglobin; Hp, haptoglobin; rHuTWEAK, recombinant human TWEAK;
125 I-rHuTWEAK, 125 I-labeled rHuTWEAK; TU, transforming unit.
FIGURE 1.
In vitro screening for peptides targeting TWEAK from a random phage display library. Microtiter plates coated with TWEAK-GST fusion protein were incubated with 2.5 ϫ 10 9 TU of a CX 7 C phage display random peptide library. Bound phage was recovered and amplified for the subsequent second and third rounds of selection on TWEAK-GST, GST, and BSA. Bound phage was quantified by counting TU plated in serial dilutions. Bars, mean Ϯ SEM from duplicate wells.
CD14, PE-anti-mouse and human Fn14/TweakR (PE-ITEM-4), or the respective isotype controls (PE-mIgG1/k, PE-mIgG2b/k, and FITCmIgG2a). For inhibition assays, monocytes were incubated with either 200 ng/ml rHuTWEAK or PBS at 4°C. Cells were then washed and left not fixed or fixed in PBS containing 2% paraformaldehyde and then treated with PE-anti-human CD163. After processing, cells were fixed in PBS containing 2% paraformaldehyde and subjected to flow cytometry analysis by using a 
Confocal immunofluorescence microscopy
CD14-positive monocytes plated overnight in the LabTek II chamber slide system (2.5 ϫ 10 5 cells/well) were incubated with 200 ng/ml rHuTWEAK or PBS for 30 min at 4°C to prevent or minimize receptor internalization. After three washes with ice-cold PBS, cells were incubated with an polyclonal goat-anti-human TWEAK Ab. A Cy3-conjugated AffiniPure F(abЈ) 2 donkey anti-goat IgG (HϩL) was used as a secondary Ab. Fixed slides mounted with fluorescent mounting medium (DakoCytomation) were examined in a confocal microscope (Olympus FV500).
Monocyte activation assay
Monocyte activation was measured by quantifying the ability of cells to metabolize the tetrazolium salt WST-1 to formazan (Roche) at 37°C (34) . CD14-positive monocytes were plated in 96-well plates (30,000 cells/ well) and incubated for 42 h with or without dexamethasone (10 ng/ml; Sigma-Aldrich), rHuTWEAK (1 g/ml) and anti-CD163 GHI/61 (1.25 g/ml). WST-1 was added for 4 h after finishing the incubation period. Absorbance was determined at 440 nm in an optical reader (Bio-Tek Instruments).
TWEAK-depleted supernatants
Freshly isolated human monocytes preincubated with or without anti-CD163 Ab for 30 min were treated with increasing concentrations of rHuTWEAK (0, 10, 50, and 100 ng/ml) for 1 h at 4°C or 24 h at 37°C. After that, monocytes were decanted by centrifugation and supernatants were frozen at Ϫ80°C until additional experiments were performed. Additional time points were also obtained by treating monocytes for 30 min and 2 h (data not shown). Alternatively, rHuTWEAK was preincubated with CWDDGWSFC or the control peptide (30 and 100 M) for 30 min before admixture into the monocyte culture.
Cell viability on TWEAK-sensitive cells
Human colon adenocarcinoma HT-29 cells were obtained from American Type Culture Collection and cultured with modified RPMI 1640 containing 10% FBS, 100 g/ml streptomycin and penicillin, and 2 mM glutamine. Cells were plated in 96-microtiter well plates (20,000 cells/ well) and pretreated with IFN-␥ (20 ng/ml; R&D Systems) for 12 h.
Then, cells were incubated with or without rHuTWEAK as indicated. After 36 h of culture, cell proliferation was assessed. To evaluate the ability of monocytes to deplete TWEAK from the medium, supernatants from monocyte cultures (as described above) were added to IFN-␥-treated HT29 cells and a cell viability assay was performed under the same conditions. To rule out the possibility of TWEAK degradation by monocyte-secreted proteins, parallel experiments were performed by using a conditioned medium of cultured monocytes incubated with or without same amounts of rHuTWEAK, and a cell viability assay was conducted (data not shown).
Transient expression of huCD163 in CHO cells
The open reading frames of CD5 and CD6 were directionally cloned in the eukaryotic vector pCMV and confirmed by DNA sequencing. Plasmids were prepared by using the GenElute HP Endotoxin-free kit (SigmaAldrich) for cell transfection. CHO cells were maintained with RPMI 1640 medium containing 5% FBS and no antibiotics. Cells were seeded at 30% confluence into 24-well plates and transfected at a ratio of 6 l of FuGENE per 1 g of DNA with the plasmids encoding human SRCR or Fn14. Twenty-four hours after transfection, the cells were washed once with PBS and fresh medium containing the adequate ligands was added. Cell surface expression of the transfectants was analyzed by the flow assay cytometry described above.
Preparation of 125 I-rHuTWEAK and Hp-Hb complexes
125 I-rHuTWEAK was prepared by using an Iodogen coating tube (Pierce) as described (35) . Briefly, 200 g of rHuTWEAK was incubated with Na 125 I (0.925 MBq) in 200 l of 0.5 M sodium phosphate buffer (pH 7.4) for 20 min at 37°C, and then dialyzed against PBS. Complexes were prepared by mixing equimolar concentrations of Hb and Hp in PBS as described (30) .
Cellular binding of 125 I-rHuTWEAK by CD163-CHO cells
Cellular binding of 125 I-rHuTWEAK was performed in accordance to that of advanced glycated end product-modified BSA by CD36 as described previously (35) . For cell binding assay, cells were incubated with 100 ng/ml 125 I-rHuTWEAK at 4°C in RPMI 1640 containing 3% BSA for 3 h. After incubation, cells were washed three times with ice-cold PBS and lysed with 0.1 M NaOH. Radioactivity and protein concentration of whole cell lysates were determined by using a gamma well counter and a BCA protein assay kit (Pierce). For inhibition assays, cells were also incubated with or without the indicated ligands (1 or 10 g/ml rHuTWEAK or Hp-Hb complexes, 100 M CWDDGWSFC or control peptide CRKFRDEATC, and 10 g/ml AM-3K anti-CD163 Ab or control mouse IgG).
Results

Identification of TWEAK-binding peptides
We isolated TWEAK-binding peptides by screening a CX 7 C phage library (22, 23) on a recombinant TWEAK-GST fusion protein (Fig. 1) . A marked enrichment in phage binding to TWEAK-GST relative to the negative controls GST (30-fold) or BSA (2,000-fold) was observed after three rounds of selection.
Analysis of peptide sequences and specificity of binding to TWEAK
Forty-nine of 158 (31%) of clones obtained from the screening displayed a WXDDG motif or some variation of it; X was preferentially a nonpolar or polar uncharged residue (Fig. 2) . Phage clones displaying the peptide sequences CWDDGWSFC, CLWTD DGYC, CYWGDDGFC, CWWFDDGYC, and CRWADDGFC were used for additional experiments. Such sequences were chosen because they were enriched or because they showed homology to candidate binding proteins. The relative binding of these peptide sequences to TWEAK in regard to negative controls was then individually determined (Fig. 3A) . Selected peptides showed an enhanced binding to TWEAK relative to GST (mean 26-fold; range 7-to 48-fold). Phage clones displaying the peptide CWDDGWSFC had the FIGURE 5. Binding inhibition of CWDDGWSFC phage to TWEAK by an anti-human CD163 mAb. Either CWDDGWSFC phage or insertless phage at 10 9 TU was incubated with 10 g/ml anti-human CD163 mouse mAb. A control isotype Ab was used as a negative control. Afterward, each solution was transferred to microtiter wells coated with rHuTWEAK or BSA and incubated for an additional 2 h. Shown is mean Ϯ SEM of a representative experiment. Three experiments were performed with similar results. highest relative binding to TWEAK (10-fold for GST and 900-fold for BSA) and bound over 800-fold more than binding of the insertless control phage. Similar results were also obtained with the purified rHuTWEAK protein. To evaluate the specificity of the interaction between CWDDGWSFC and TWEAK, we tested whether CWDDGWSFC-phage binding to TWEAK was inhibited when immobilized rHuTWEAK was preincubated with an anti-TWEAK Ab. CWDDGWSFC-displaying phage binding (but not binding of the control phage) was inhibited (Fig. 3B) . Together, these data indicate that the CWDDGWSFC interacts specifically with TWEAK.
Mapping of peptide sequences to CD163
Peptide sequences obtained from the phage selection (n ϭ 158) were analyzed for similarity to known human proteins by using the NCBI BLAST software. Of these sequences, 41 (26%) matched motifs found within the CD163 protein (NCBI protein database accession no. NP_004235). CD163 is a member of the SRCR superfamily and is expressed on the human monocyte and macrophage lineage. An alignment of a subset of peptide sequences isolated from panning on TWEAK with the protein sequence of CD163 was assembled (Fig. 4) . Because the CWDDGWSFC peptide aligned to different sites of the CD163 sequence (data not shown), we estimate a total of 44 putative interacting sites between TWEAK and CD163. As predicted, all sites located to the extracellular domain containing the SRCR of the CD163 protein.
CWDDGWSFC mimics CD163
Based on these observations, we hypothesized that the selected TWEAK-binding phage clones mimic CD163. To test this hypothesis, we evaluated the specific recognition of the CWDDGWSFCphage by an anti-CD163 mAb raised against the N-terminal domain of the protein (which includes the cysteine-rich domain). We next performed a binding experiment in vitro in which the CWDDGWSFC-phage or the control phage was preincubated with anti-CD163 mAb or an isotype control. The anti-CD163 mAb inhibited the binding of the CWDDGWSFC-phage to immobilized rHuTWEAK, whereas the isotype control did not exert any detectable blocking effect (Fig. 5) . This result suggests that the CWDDGWSFC peptide mimics, at least partially, the epitope recognized by the anti-CD163 mAb.
TWEAK exhibits similarity to a native CD163 ligand
The SRCR CD163 was identified as a specific Hb scavenger receptor that mediates the uptake of Hb in complex with Hp (i.e., the Hp-Hb complex; Refs. 29 and 36). A search for similarities in the protein sequences of TWEAK, Hp, and Hb led to several observations. First, TWEAK (NCBI protein database accession no. NP_003800) and Hp (NCBI protein database accession no. NP_005134) each contained a region consisting of a 31-residue motif with 13 identical amino acids and six amino acids with the same hydropathic profile (Fig. 6A) . This region represents 19% of secreted TWEAK (residues 95-249) and 12% of the Hp ␤-chain (residues 162-406). We also observed that the residues 11-25 in the Hb ␤-chain (NCBI protein database accession no. P02023), which are also implicated in Hp-Hb complex formation (37) , matched a region comprising amino acids 154 -172 in TWEAK (Fig. 6B ). This segment in TWEAK is separated by only seven residues from the domain homologous to Hp (Fig. 6C) . Finally, the CDR3 of a Fab Ab (10 residues; sequence EDTTDWYFDV) that blocks the binding of Hp-Hb complex to CD163 (38) revealed Ͼ50% homology with the CWEDTLDWC peptide (Fig. 4 ) and ϳ40% homology with the CWYLFDEPC peptide (Figs. 6D and 2 ) of the screening. 
TWEAK binds to CD163
To support our hypothesis, we evaluated the binding of rHu TWEAK to CD163. We show that TWEAK binds specifically to CD163 in a dose-dependent manner (Fig. 7, A and C) . As controls, binding to Fn14/TweakR but not to an unrelated receptor (variable endothelial growth factor receptor) or BSA are shown (Fig. 7A) . Human EGF, IL-2, and IL-11 also failed to bind to CD163 (Fig. 7B) . Next, we showed that TWEAK binding to CD163 is inhibited by a CWDDGWSFC synthetic peptide in a dose-dependent manner; a control peptide with an unrelated sequence had no effect (Fig. 7D) . We sought to determine whether the addition of the soluble receptor would interfere with the TWEAK binding. Soluble CD163 preincubated with rHuTWEAK was able to inhibit the binding to Fn14/TweakR (Fig. 7E, left panel) . In contrast, Fn14/ TweakR preincubated with rHuTWEAK also inhibited TWEAK binding to CD163 (Fig. 7E, right panel) suggesting a competition between both receptors. Recently, Madsen et al. (39) described ligand-binding properties of the membrane-associated CD163 protein and identified the SRCR domains involved in Hp-Hb and Ab binding. Thus, we next evaluated whether preincubation with three different clones of anti-CD163 Abs (Ki-M8, GHI-61, and 10D6) could inhibit TWEAK binding to CD163. Consistent with our findings, all the three Abs inhibited TWEAK binding to CD163 (Fig. 7F ).
Fn14/TweakR-negative/CD163-positive human monocytes specifically bind TWEAK
Because TWEAK is not present at detectable levels on the surface of freshly isolated monocytes (9), we asked whether monocytes would bind TWEAK. CD14-positive monocytes, selected because this subset of cells displays the highest expression of CD163 among monocytes (26), did not show expression of TWEAK on the surface after 18 h in culture (Fig. 8A) ; however, we detected TWEAK binding at the cell surface after incubation with rHuTWEAK (Fig. 8B) . To further investigate the protein responsible for TWEAK binding in CD14-positive human monocytes, we first evaluated the expression of Fn14/TweakR and that of CD163. Flow cytometry revealed no expression of the recently identified receptor of TWEAK (Fn14/TweakR; Refs. 16 and 17) , suggesting the presence of another TWEAKbinding protein on CD14-positive human monocytes. In contrast and in agreement with previous reports (26), we found a high expression of CD163 in 40% of CD14-positive monocytes, (Fig. 9, A and B) . To determine whether TWEAK and CD163 interact specifically at the surface of human monocytes, we analyzed the expression of CD163 after the preincubation of freshly isolated CD14-positive cells with TWEAK. We found that the detection of CD163 with an anti-CD163 mAb was inhibited in the presence of TWEAK, but no effect was noted when the cells were preincubated with PBS alone (Fig. 9C) . Collectively, these data are consistent with a specific interaction between TWEAK and CD163 on the cell surface of Fn14/ TweakR-negative human monocytes.
Monocyte activation induced by an anti-CD163 Ab is inhibited by TWEAK
We evaluated whether TWEAK and CD163 can interact functionally. Cross-linking of the CD163 receptor by an anti-CD163 mAb induces signaling and macrophage activation (28) . There are two technical considerations that may well be relevant to interpreting this set of experiments. First, culturing normal monocytes results in an ϳ60% decrease in cell number after 48 h, with most of those cells being lost during the first 6 h of culture (40) . Second, the ability of viable cells to metabolize tetrazolium salts (indicated as WST-1 reduction), generally used as a quantitative measure of cell number, can also reflect cell activation from an increase in the overall activity of mitochondrial dehydrogenases (34, 41) .
We sought to determine whether incubation with the anti-CD163 Ab GHI/61 activated CD14-positive human monocytes and whether coincubation with TWEAK changed such an effect. The ability of cells to metabolize tetrazolium salts was used as a cell activation marker to evaluate differences in cell viability (34) . Activation was higher for monocytes incubated with anti-CD163 Ab relative to buffer (Fig. 10A) or isotype control (data not shown). This effect was abrogated by the addition of rHuTWEAK. In comparison to control cultures, monocytes incubated with rHu TWEAK alone showed no difference in activation level. The addition of dexamethasone, which up-regulates CD163 (24), did not change the results. Thus, TWEAK appears to inhibit anti-CD163-Ab-induced activation by competing for the same or perhaps a close overlapping binding site (Fig. 10A) .
TWEAK-mediated programmed cell death can be inhibited by preincubation with monocytes
TWEAK-induced programmed cell death in several tumor cell lines has been extensively characterized. In particular, Nakayama et al. (12) described the mechanisms mediating the apoptosis of IFN-␥-treated HT-29 cells. Based on the results described above, we hypothesized that CD163, a scavenger receptor, might be acting as a receptor "decoy" for the ligand TWEAK. To test this hypothesis experimentally, we evaluated whether human monocytes (either freshly isolated or after plating for 24 h) could bind and functionally sequester the rHuTWEAK added to the culture medium. Indeed, we show that the ability of TWEAK to induce apoptosis is abrogated from TWEAK-containing monocyte supernatants compared with controls (Fig. 10B) . To rule out the possibility that TWEAK was actually being degraded or consumed by monocyte-secreted proteins, we incubated monocyte-conditioned medium (collected at 30 min and at 1 and 2 h) with the same amounts of TWEAK used above. No differences were observed compared with the curve for untreated TWEAK (data not shown). Moreover, TWEAK-mediated programmed cell death was observed when monocytes were treated with an anti-CD163 Ab (Fig.  10B) or by preincubating TWEAK with the CWDDGWSFC peptide (Fig. 10C) .
Cellular binding of 125 I-rHuTWEAK to CD163
To examine the cellular interaction of CD163 with TWEAK, we determined the binding of 125 I-rHuTWEAK by SRCR (CD163, CD5, and CD6) or TWEAK receptor Fn14 compared with mock-transfected CHO cells. Fig. 11A shows that CHO cells transiently expressing CD163 exhibited the specific binding of 125 I-rHuTWEAK but that mock-transfected CHO cells did not. As positive control, 125 I-rHuTWEAK bound to the Fn14-expressed cells. In contrast, CHO cells expressing CD5 or CD6 have no specific binding activity. These results indicate that TWEAK is specifically recognized by CD163 as well as Fn14, but not by CD5 and CD6. Cell membrane expression of CD163, CD5, CD6, and Fn14/TweakR on CHO cells was demonstrated by flow cytometry (Fig. 11B) .
Next, we examined the effects of various ligands and Abs on the binding of TWEAK to the CHO cells transiently expressing CD163.
125 I-rHuTWEAK binding to the CD163 was inhibited completely by unlabeled rHuTWEAK in a dose-dependent manner and almost inhibited by an excess of Hb-Hp complexes (Fig. 11C) . In addition, the CD163-like peptide CWDDGWSFC and the anti-CD163 mAb AK-3K (30) also decreased this activity by 15 and 37%, respectively. By contrast, two controls (CRKFRDEATC peptide and mouse IgG) had no effects. Furthermore, CD163-CHO cells mediated the specific degradation of 125 I-rHuTWEAK, but mock-transfected or cells expressing CD5 or CD6 had no such activity (data not shown). These results indicate that the TWEAK binding site(s) within CD163 shares their recognition site(s) with that of Hb-Hp complexes, suggesting that CD163 serves as a scavenger receptor for both ligands.
Discussion
Several studies based on TWEAK-induced migration, proliferation, and angiogenesis in endothelial cells and apoptosis in tumor cells have long suggested a role for the TWEAK receptor Fn14/ TweakR (1-3, 17) . However, the wide range of biological effects in cells deficient for that receptor raises the possibility that cells may express other TWEAK receptors. First, we screened a combinatorial library to find TWEAK-binding peptides and found motifs similar to that of CD163. Moreover, we validated functional protein-protein interactions between TWEAK and CD163. Finally, we show that the binding is specific. The findings reported here support the candidacy of the cell surface protein CD163 as a TWEAK-binding protein and a possible alternative TWEAK receptor in Fn14/TweakR-deficient cells.
After the selection of a random peptide library on immobilized TWEAK, marked enrichment was obtained. Upon DNA sequencing of the selected phage clones, it became apparent that many of the peptides displayed contained the predominant motif WXDDG or its permutations (flanked by cysteine residues engineered into the libraries). Of note, we have previously identified similar peptide motifs as structural sites in certain integrins (19) and aminopeptidases (22) , indicating that this motif is both conserved in several protein families and functional in ligand-receptor binding interactions.
In this study, sequence homology analysis of the predominant motifs recovered from the selection (Figs. 2 and 4) suggest that the peptides mimic the structure of CD163, a member of the class B SRCR restricted to the monocyte/macrophage lineage. SRCR domains are widely found in cell surface molecules where they are thought to mediate ligand binding (39) ; in particular, the CD163 sequence has nine extracellular cystein-rich domains. Indeed, repeated units of cysteine clusters also define the TNFR superfamily (42) . The presence of this motif suggested the possibility that such domains may mediate a putative protein interaction between TWEAK and CD163. The crystal structure of another member of the SRCR family, the glycoprotein M2BP (Mac-2 binding protein; M2BP) (43) , has been considered a general template for the cysteine-rich domains in proteins of this ancient superfamily (43, 44) , including CD163. It consists of a curved six-stranded ␤-sheet cradling an ␣-helix. When TWEAK-binding peptides were aligned with the CD163 sequence, the putative sites of interaction were identified in eight of the nine cysteine-rich domains (excepting SRCR5), 42 peptides were matched to the ␤-sheets, and only two were matched to the corresponding ␣-helix of SRCR2 (residues 192-196) and SRCR9 (residues 954 -960). No peptide appeared to interact with the transmembrane or intracellular domains, indicating that the interactions are limited to regions of the protein known to be extracellular. Supporting these observations, an anti-CD163 mAb inhibited binding of the CWDDGWSFC phage, which displays a peptide that matches several different regions of the extracellular domain of CD163, to TWEAK.
Other unexpected aspects of our results merit further discussion. The CD163 macrophage-restricted Ag is an established scavenger receptor of circulating Hp-Hb complexes (29, 36) , but not of Hp or Hb separately (29) . The binding region to CD163 is likely to be represented by structural components created by both Hp and Hb molecules or by an unfolding of a neo-epitope upon complex formation. The residues in the complexes containing the CD163-recognition site have not yet been characterized. However, the Hp ␤-chain (the major protein of the complex) harbors the receptorrecognition site exposed during complex formation because of its location in Hp (45, 46) . Comparison of protein sequences of TWEAK with Hp and Hb reveals similarity in a region that comprised Ͼ30% of the secreted TWEAK. In addition, the hypervariable region of a Fab Ab that specifically recognizes the Hp-Hb complex revealed Ͼ40% homology with two TWEAK-binding peptides isolated from our panning, supporting the hypothesis that TWEAK may also mimic a neo-epitope generated in the Hp-Hb complex (37).
Madsen et al. (39) have recently shown that the anti-CD163 Ab clone Ki-M8 blocks the binding of the ligand complexes to SRCR domain 3 while clone GHI/61 binds to SRCR domain 7, not affecting the specific ligand-binding site. In this study we have shown that TWEAK binds in vitro to purified CD163 in a dosedependent manner and that this binding is inhibited by preincubation of CD163 with mAbs raised against CD163. Moreover, TWEAK binding to Fn14/TweakR or CD163 can be displaced by the addition of the opposite soluble receptor, indicating a competition between both receptors. These results lend further support to our hypothesis of a TWEAK-CD163 protein interaction.
Because CD163 is expressed exclusively on monocytes and macrophages, we investigated the putative interactions of TWEAK and CD163 in this cell lineage. In agreement with previous reports (9), the established TWEAK receptor is not present at detectable levels on the surface of freshly isolated CD14-positive monocytes from healthy human donors. Nevertheless, such cells are capable of binding TWEAK as shown here. Thus, CD14-positive/CD163-positive cells not expressing Fn14/TweakR still bind TWEAK.
These results suggest that other receptor(s) may mediate the interaction. We show that preincubation with TWEAK inhibited recognition by a specific Ab of CD163 on the monocyte surface.
Therefore, we used cross-linking of CD163 by a specific Ab to activate tyrosine kinases in human monocytes. Given that the CD14-positive human monocytes in our system were nonproliferating (40) , we demonstrated that incubation with an anti-CD163 Ab induced a metabolic activation relative to controls. Coincubation with TWEAK abrogated this activation. In contrast, monocytes incubated with TWEAK alone showed no change in the same conditions. Thus, TWEAK can inhibit the activating effect of the anti-CD163 mAb through biochemical competition for the binding site, steric hindrance, or both.
Also, we have shown that human monocytes can sequester soluble TWEAK from the culture medium. Consistently, monocytes are not able to bind TWEAK in the presence of either an anti-CD163 mAb or a peptide motif mimicking CD163. In light of these findings, TWEAK and CD163 seem to be functionally linked. In addition, TWEAK mediates monocyte death induced by autologous T cells in patients with certain autoimmune diseases (10) and previous reports have shown that TWEAK is produced by monocytes stimulated by IFN-␥, an anti-inflammatory cytokine that also negatively regulates CD163 (26) , again suggesting that both proteins function in interacting pathways.
Finally, by using CHO cells transiently expressing the scavenger receptor CD163, we demonstrated that rHuTWEAK specifically binds to this receptor in a similar manner as to its natural receptor (Fn14/TweakR); such binding is reverted by unlabeled rHuTWEAK or the Hp-Hb complex. Moreover, the CD163 receptor also mediates rHuTWEAK degradation (data not shown), an observation consistent with a scavenger function for this ligand.
In summary, our results demonstrate that a protein-protein interaction occurs between TWEAK and CD163 at the cell surfaces of human CD14-positive monocytes. Several lines of evidence are presented in support of this hypothesis. First, phage clones displaying peptides that bind to TWEAK mimic the several SRCR domains in CD163. Furthermore, we also observed that the TWEAK protein structure mimics the Hp-Hb complex, an established CD163 ligand. TWEAK and CD163 also interact at the surface of Fn14/TweakR-negative human monocytes, and TWEAK competes for CD163 binding to these cells. Recently, it was reported that TWEAK promotes tumor cell invasion rather than apoptosis (47) , an event that correlates with the overexpression of Fn14/TweakR. According to our findings, it could be proposed that CD163 is a scavenger receptor for TWEAK, thus preventing TWEAK from exerting its biological function(s) by sequestering it from the tumor environment. In accordance with the competition between TWEAK and Hp-Hb shown in the binding experiment, one might also propose that TWEAK could act as an antagonist for CD163. Future research efforts regarding the functional effects of TWEAK-CD163 interaction need to be performed to validate one of these hypotheses. A detailed understanding of this possible functional link between TWEAK and CD163 may have impact on conditions such as inflammation and cancer (10, 47, 48) .
